The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The collaboration will center on expanding access to Eastman’s Esmeri technology
The new functionality complements Parse’s existing Evercode immune products
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Subscribe To Our Newsletter & Stay Updated